20 May 2013
Keywords: palatin, az, extend, melanocortin, receptor, alliance, usa
Article | 15 December 2008
The USA's Palatin Technologies has extended its R&D collaboration and license agreement with Anglo-Swedish drug major AstraZeneca focused on
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 December 2008
© 2013 thepharmaletter.com